Skip to main navigation menu Skip to main content Skip to site footer
×
Español (España) | English
Editorial
Home
Indexing
Review

The Role of Denosumab and Bisphosphonate in Osteogenesis Imperfecta: A Literature Review

By
Agus Kresnadi ,
Agus Kresnadi

Airlangga University/Dr. Soetomo General Academic Hospital, Department of Orthopaedic and Traumatology, Surabaya, Indonesia

Search this author on:

PubMed | Google Scholar
Tri Wahyu Martanto ,
Tri Wahyu Martanto

Airlangga University/Dr. Soetomo General Academic Hospital, Department of Orthopaedic and Traumatology, Surabaya, Indonesia

Search this author on:

PubMed | Google Scholar
Arif Zulkarnain ,
Arif Zulkarnain

Airlangga University/Dr. Soetomo General Academic Hospital, Department of Orthopaedic and Traumatology, Surabaya, Indonesia

Search this author on:

PubMed | Google Scholar
Hizbillah Yazid ,
Hizbillah Yazid

Airlangga University/Dr. Soetomo General Academic Hospital, Department of Orthopaedic and Traumatology, Surabaya, Indonesia

Search this author on:

PubMed | Google Scholar

Abstract

Osteogenesis Imperfecta (OI) is a rare genetic disorder characterized by brittle bones and susceptibility to fractures. Management of OI focuses on minimizing fractures and improving bone strength. Denosumab and bisphosphonates have emerged as potential therapeutic agents in OI management due to their ability to modulate bone turnover. This literature review aims to explore the role of denosumab and bisphosphonates in the treatment of OI, highlighting their mechanisms of action, efficacy, and safety profiles. A comprehensive search was conducted across various databases, to identify relevant studies investigating the use of denosumab and bisphosphonates in OI management. The review discusses the molecular pathways underlying the pathogenesis of OI and how denosumab and bisphosphonates intervene in these pathways to improve bone quality. Furthermore, the review summarizes the findings from clinical trials and observational studies evaluating the effectiveness of denosumab and bisphosphonates in reducing fracture rates, improving bone mineral density, parathyroid hormone changes, calcium and phosphate quantity, and also enhancing functional outcomes in patients with OI. Additionally, considerations regarding optimal dosing, timing of initiation, and potential adverse effects of denosumab and bisphosphonates in individuals with OI are discussed. The synthesis of existing evidence underscores the promising role of denosumab and bisphosphonates as adjunctive therapies in the management of OI, although further research is warranted to elucidate their long-term efficacy and safety profiles in this patient population.

How to Cite

1.
Kresnadi A, Martanto TW, Zulkarnain A, Yazid H. The Role of Denosumab and Bisphosphonate in Osteogenesis Imperfecta: A Literature Review. Salud, Ciencia y Tecnología [Internet]. 2024 Apr. 4 [cited 2024 May 28];4:894. Available from: https://revista.saludcyt.ar/ojs/index.php/sct/article/view/894

The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.

Article metrics

Google scholar: See link

Metrics

Metrics Loading ...

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.